Thus, further studies are needed to analyze in greater detail the results we have highlighted here, concerning insulin neuroprotection during in vitro ischemia associated with DMT1 expression and function, and also the most recent evidence produced by the trials of both Lixisenatide and intranasal insulin in neurodegenerative diseases. Here, SLC11A2 is linked to neurodegenerative disease.